ProfileGDS5678 / 1439912_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 37% 37% 36% 36% 36% 36% 37% 36% 37% 37% 37% 37% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9296439
GSM967853U87-EV human glioblastoma xenograft - Control 22.8525437
GSM967854U87-EV human glioblastoma xenograft - Control 32.8563637
GSM967855U87-EV human glioblastoma xenograft - Control 42.7730936
GSM967856U87-EV human glioblastoma xenograft - Control 52.7815136
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9117636
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8788736
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8228337
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8002836
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8352237
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8266937
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8178237
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8438537
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8433937